Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nigelle 5 for Prevention of Influenza-like Illnesses and COVID-19
NCT04989101Completed
- Sponsor
- Hôpital Universitaire Sahloul
- Start
- Jun 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of nigella sativa in coronavirus disease 2019 (COVID-19) and influenza-like illness (ILI) (2 arms), sponsored by Hôpital Universitaire Sahloul. Primary endpoint: SarsCOV2 Infection at 1 month. Started Jun 2021; status: completed.
02
Drugs
nigella sativa
03
Conditions
coronavirus disease 2019 (COVID-19)influenza-like illness (ILI)
Beyond the preview
Go deeper on NCT04989101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989101.